Advancing the Understanding of Seborrheic Keratosis

May 2017 | Volume 16 | Issue 5 | Original Article | 419 | Copyright © May 2017


Susan C. Taylor MD

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

REFERENCES

  1. Hafner C, Vogt T, Landthaler M, et.al. Somatic FGFR3 and PIK3CA mutations are present in familial seborrheoeic keratoses. British J Dermatol. 2008;159:214-217. 
  2. Wilmer EN, Gusafaon CJ, Ahn CS, et al. Most common dermatologic conditions encountered by dermatologists and nondermatologists. Cutis. 2014;94:285-292. 
  3. Bickers DR, Lim HW, Margolis D, et.al. The burden of skin diseases: 2004 A joint project of the American Academy of Dermatology Association and the Society for Ivestigative Deramtology. J Am Acad Dermatol. 2006;55:490- 500. 
  4. Gill D, Dorevitch A, Marks R. The prevalence of seborrheic keratoses in people aged 15 to 30 years: is the term senile keratosis redundant? Arch Dermatol. 2000;136:759-62. 
  5. Rongioletti F, Corbella L, Rebora A. Multiple familial seborrheic keratoses. Dermatologica. 1988;176:43-45. 
  6. Yeatman JM, Kilkenny M, Marks R. the prevalence of seborrhoeic keratoses in an Australian population: does exposure to sunlight play a part in their frequency? Br J Dermatol. 1997:137:411-14. 
  7. Kwon OS, Hwang EJ, Bae JH, et al. Seborrheic keratosis in the Korean males: causative role of sunlight. Photodermatol Photoimmunol Photomed. 2003;19:73-80. 
  8. Logie A, Dunois-Larde C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005;14(9):1153-1160. 
  9. Stinco G, Errichetti P, Patrone P. Ungual seborrhoeic keratosis: report of a case and its dermoscopic features. J Eur Acad Dermatol Venereol. 2016;30:446-556. 
  10. Del Rosso J. A closer look at seborrheic keratoses: patient perspectives, clinical relevance, medical necessity, and implications for management. J Clin Aesthetic Dermatol. 2017;10:16-25. 
  11. Kyriakis, KP, Alexoudi I, Askoxylaki K, et al. Epidemiologic aspects of seborrheic keratosis. Int J Dermatol. 2012;51:233-237. 
  12. Roh NK, Hahn HJ, Lee YW, et al. Clinical and histopathological investigation of seborrheic keratosis. Ann Dermatol. 2016;28(2):152-8. 
  13. Niang SO, Kane A, Diall M, et al. Dermatosis papulos nigra in Dakar, Senegal. Int J Dermatol. 2007;46:45-47. 
  14. Hafner C, Landthaler M, Mentzel T, et.al. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra. Br J Dermatol. 2010;162(3):508-12. 
  15. Chakradeo K, Narsinghpura K, Ekladious. Sign of Leser-Trelat. BMJ Case Rep 2016 AaPii:bcr2016215316. Doi:10.1136/bcr-2016-215316. 
  16. Mathez ALG, Moroto D, Dib SA, Roberto de Sa J. Seborrheic keratoses and severe hypoinsulinemic hypoglycemia associated with insulin grow factor 2 secretion by a malignant solitary fibrous tumor. Diabetol Metab Sundr. 2016;8:33). 
  17. Ginarte M, Garcia-Caballero T, Rernandez-Redondo V, et.al. Expression of growth hormone receptor in benign and malignant cutaneous proliferative entities. J Cutan Pathol. 2000;27:276-282. 
  18. Izikson L, Sober AJ, Mihm MC, et.al. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis on 9204 cases. Arch Dermatol. 2002;138:1562-6. 
  19. Hafner C, Hartmann A, vanOers JMM, et.al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Modern Pathol. 2007;20:895-903. 
  20. Hafner C, Toll A, Fernandez-Casado A, et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA. 2010;107:20780-5. 
  21. Neel VA, Todorova K, Want J, et.al. Sustained Akt activity is required to maintain cell viability in seborheic keratosis, a benign epithelial tumor. J Invest Dermatol. 2016;136:696-705. 
  22. Maize JC, Snider RL. Nonmelanoma skin cancers in association with seborrheic keratoses. Clinicopathologic correlations. Dermatol Surg. 1995;21:960- 962. 
  23. Lin J, Han S, Cui L, et.al. Evaluation of dermoscopic algorithm for seborrheic keratosis: a prospective study in 412 patients. JEADV. 2014;28:957-962. 
  24. Carrera C, Sequra S, Aquilera P, et al. Dermoscopic clues for diagnosing melanomas that resemble seborrheic keratosis. JAMA Dermatol. 2017; Doi:10.1001/jamadermatol 2017.0129. 
  25. Conic RX, Napekoski K, Schuetx H, et al. The role of immunosuppression in squamous cell carcinomas arising in seborrheic keratosis. J Am Acad Dermatol. 2017 (In press; http://dx.doi.org/10.1016/j.jaad.2016.12.002) 
  26. Kim W-J, Lee K, Song M, et al. Clinical clues for differential diagnosis between verruca plans and verruca plana-like seborrheic keratosis. J of Dermatol. 2015;42:373-377. 
  27. Duque MI, Jordan JR, Fleischer AB, et al. Frequency of seborrheic keratosis biopsies in the United States: A benchmark of skin lesion care quality and cost effectiveness. Dermatol Surg. 2003;29:796-801. 
  28. Herron MD, Bowen AR, Krueger GG. Seborrheic keratoses: A study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol. 2004;43:300-2. 
  29. Gurel MS, Aral BB. Effectiveness of erbium:YAG laser and cryosurgery in seborrheic keratoses: Randomized, prospective intraindividual comparison study. J Dermatol Treat. 2015;26(5):477-80. 
  30. Cuevas P, Angulo J, Salgüero I, et al. Clearance of seborrhoeic keratoses with topical dobesilate. BMJ Case Rep. 2012;2012. pii: bcr0120125628. 
  31. Levy-Nissenbaum E, Thio HB, Burstein P, et.al. Seborrheic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL- 5010). Br J Dermatol. 2015;173:247-249. 
  32. Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition. https://www.drugs.com/clinical_trials/aclaris-therapeutics-announces-positive-top-line-phase-3-results-101-treating-seborrheic-keratosis-17248.html. 

AUTHOR CORRESPONDENCE

Susan C. Taylor MD E-mail:................................................... [email protected]